Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 4/20 | 0.37 |
| ▸ | RARB | P10826 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 4/20 | 0.35 |
| ▸ | RXRG | P48443 | 3/20 | 0.35 |
| ▸ | RXRB | P28702 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7755839 | 1.00 | RARA (0.37) | RARARARBSMN1; SMN2RARGCYP4F2 | |
| SCHEMBL7757749 | 0.91 | TDP1 (0.38) | RARARARBRARGRXRARXRG | |
| SCHEMBL7757751 | 0.91 | TDP1 (0.38) | RARARARBRARGRXRARXRG | |
| SCHEMBL7781815 | 0.88 | RXRA (0.44) | RARARARBRARGRXRARXRG | |
| SCHEMBL7781817 | 0.88 | RXRA (0.44) | RARARARBRARGRXRARXRG | |
| SCHEMBL7755022 | 0.79 | RARB (0.53) | RARARARBSMN1; SMN2RARGRXRA | |
| SCHEMBL7755028 | 0.79 | RARB (0.53) | RARARARBSMN1; SMN2RARGRXRA | |
| SCHEMBL7755067 | 0.72 | RXRA (0.47) | RARARARBRARGRXRARXRG | |
| SCHEMBL7755074 | 0.72 | RXRA (0.47) | RARARARBRARGRXRARXRG | |
| SCHEMBL7755311 | 0.72 | RXRA (0.57) | RARARARBRARGRXRARXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010037025-A1 | New compounds, their preparation and use | MURRAY ANTHONY (DK) | 2001-11-01 | — | — | US | disclosed |
| EP-1077919-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058486-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037025-A1 | New compounds, their preparation and use | GPR119, SLC5A1, SLC5A2 | RARA 1587/4885RARB 1697/4885SMN1; SMN2 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.